Following a resubmission
Calcipotriol/betamethasone dipropionate ointment (Dovobet®) is accepted for restricted use within NHS Scotland for the initial topical treatment of stable plaque psoriasis. Short-term comparisons have shown that the combination is more effective than either component as monotherapy and that it is cost effective compared to alternative therapies.
Its use is restricted to physicians experienced in treating inflammatory skin disease. Dovobet contains a potent steroid, the use of which carries risks of destabilising psoriasis and side effects from prolonged use. The duration of treatment should not exceed four weeks.
Download detailed advice71KB (PDF)
- Medicine name:
- Calcipotriol and betamethasone ointment (Dovobet®)
- SMC ID:
- Stable plaque psoriasis vulgaris amenable to topical therapy
- Pharmaceutical company
- LEO Pharmaceuticals
- BNF chapter
- Submission type
- Date advice published
- 12 December 2005